Akari Therapeutics Plc Stock News

This week, we take an in-depth look at sparsely followed Akari Therapeutics. The company is taking an unusual route to develop treatments of rare and orphan dis

The patent disputes over the leading drug forced Alexion to seek the revenue diversification. The recent acquisitions are unlikely to accelerate the current gro

The owner of a building on Middle Street hired 2 armed guards after businesses were damaged or burglarized the previous night.

Institutions around the world are working to find treatments and vaccines for COVID-19, the novel coronavirus. The pathway is a long and difficult one.

Open pivotal study in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) with orphan and fast track approval Preparing for pivotal study.

Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4)

Alexion Announces Upcoming Data Presentations at the Virtual 25th Congress of the European Hematology Association

The

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

Akari announced positive top line Phase 2 data. Athersys progresses with multistem COVID-19 therapy. SCWorx announces cancellation of COVID-19 test kit order.

Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) syst

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Akari Therapeutics (AKTX – Research Report) today and set a

Study achieved primary endpoint of no drug-related serious adverse events and main secondary efficacy endpoints with 7 of the 9 treated patients showing a rapid and clinically.

B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Akari Therapeutics (AKTX – Research Report) today and set a

Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date - Interim Phase II bullous pemphigoid (BP) data demonstrated a rapid and.